MASC 03.18/TROG 21.01 - I-MAT - TROG Cancer Research

By w.paterson
21 June, 2021
0 Comments

A randomised, placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma

Primary Sponsor

Melanoma and Skin Cancer Trials Limited (MASC Trials)

Collaborating Groups

TROG Cancer Research

Trial Chairperson

Dr Wen Xu, Princess Alexandra Hospital, QLD

TOPGEAR trial results published in the New England Journal of Medicine

18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

11 September, 2024

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

11 September 2024: Our 2024 Annual Scientific Meeting was

Join us to raise $35,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A randomised, placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma

TROG 13.01 – SAFRON II /ALTG 13.001

TROG 18.06 – FIG

Related Post

TOPGEAR trial findings published in NEJM

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

Join us to raise $35,000